HIV/AIDS Clinical Care: Meetings

More from HPTN 052

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Initiation of antiretroviral therapy in HIV-infected adults at CD4 counts >350 cells/mm³ significantly reduced the incidence of clinical events and is cost-effective, according to two analyses presented at AIDS 2012.

• By Carlos del Rio, MD
• September 10, 2012

Cobicistat Noninferior to Ritonavir in Boosted PI–Based Regimen

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Cobicistat proved as safe and effective as ritonavir in a study presented at AIDS 2012.

• By Keith Henry, MD
• September 10, 2012

HIV Cure Research Takes Center Stage

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Researchers at AIDS 2012 reported that two patients had clearance of HIV reservoirs following allogeneic stem cell transplant — a tantalizing finding that raises new questions for cure research.

• By Rajesh T. Gandhi, MD
• September 10, 2012

Dolutegravir Noninferior to Raltegravir in Treatment-Naive HIV-Infected Patients

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

A 48-week analysis presented at AIDS 2012 showed virologic suppression rates of 88% for dolutegravir and 85% for raltegravir.

• By Charles B. Hicks, MD
• August 20, 2012

Switching PI-Based ART to a Single-Tablet Regimen — Safe and Effective

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Switching to tenofovir/FTC/rilpivirine from a boosted protease inhibitor–based regimen worked well, according to data presented at AIDS 2012.

• By Charles B. Hicks, MD
• August 20, 2012

Caution About Two-Drug Regimens Containing Maraviroc plus a Boosted PI

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

In two small studies presented at AIDS 2012, suboptimal treatment responses were seen with regimens consisting of maraviroc plus boosted atazanavir or boosted darunavir.

• By Paul E. Sax, MD
• August 20, 2012

INH for Prevention of TB — Still the Standard, But For How Long?

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Data presented at AIDS 2012 demonstrated the efficacy of isoniazid among patients on ART but also highlighted the potential of weekly INH plus rifapentine.

• By Helmut Albrecht, MD
• August 20, 2012

Raltegravir-Based ART in HIV-Related TB

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

A small comparative trial presented at AIDS 2012 demonstrated similar virologic efficacy for efavirenz, standard-dose raltegravir, and double-dose raltegravir.

• By Paul E. Sax, MD
• August 20, 2012

Sutezolid, a Potential New Weapon Against TB

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Sutezolid was active against TB in a small 14-day trial presented at AIDS 2012, but more data are needed before we can know the true potential of this drug.

• By Helmut Albrecht, MD
• August 20, 2012

Report from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

An expert's take on the most clinically relevant reports from this year's resistance meeting

• By Daniel R. Kuritzkes, MD
• July 9, 2012